key: cord-0724355-n38wavji
authors: Nelli, F.; Fabbri, A.; Onorato, A.; Giannarelli, D.; Silvestri, M.A.; Berrios, J.R. Giron; Virtuoso, A.; Marrucci, E.; Signorelli, C.; Chilelli, M.G.; Primi, F.; Schirripa, M.; Mazzotta, M.; Ruggeri, E.M.
title: Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: Preliminary results from the prospective observational Vax-On study.
date: 2021-09-20
journal: Ann Oncol
DOI: 10.1016/j.annonc.2021.09.009
sha: 19b362ec4dcc97d897635c9ba012c13326fea6d6
doc_id: 724355
cord_uid: n38wavji

nan

National health plans prioritized cancer patients on active treatment for SARS-CoV-2 vaccination because of high morbidity and mortality rates associated with COVID-19 1 . The mRNA vaccine approval studies excluded recipients of immunosuppressive therapy [2] [3] , raising concerns among the oncology community. Herein, we assessed the effects of active treatments on safety and immunogenicity of SARS-CoV-2 mRNA-BNT162b2 vaccine in patients with solid malignancies. This cohort study prospectively enrolled patients who started the three-week apart mRNA-BNT162b2 vaccine schedule from March 9 to April 12, 2021 (timepoint-1). Those on active treatment within the previous 28 days accounted for the exposed cohort (ExC). Patients who had discontinued such treatment by at least 28 days represented the control cohort (CC). Safety analysis and quantification of anti-SARS-CoV-2 Spike IgG were performed before the second dose (timepoint-2) and 8 weeks thereafter (timepoint-3). The titration was performed using the Abbott SARS-CoV-2 chemiluminescent microparticle immunoassay and seroconversion was defined at ≥50 AU/mL IgG titer. No SARS-CoV-2 rRT-PCR swab test or serologic titer was required at baseline. The study was approved by referring Ethics Committee (Protocol N.595/CE Lazio1) and formally registered (EudraCT N.2021-002611-54).

Cohorts were compared using appropriate tests for categorical and continuous variables. We enrolled 366 patients (81 in the CC and 285 in the ExC) and the cohorts were mostly homogeneous (Supplementary Figure S1 and Table S1 ). The adjuvant chemotherapy setting, prevalent in control cohort, accounts for the difference. Severe adverse events were rare (1%). The most common adverse reactions were mild injection site reactions. Systemic adverse events did not exceed 17% of cases (Supplementary Table S2 ) and were significantly associated with specific features (i.e. female sex, ECOG PS2 or G-CSF use, Supplementary Figure 1A ), and seroconversion rate (65% vs 52%, P=0.048; Figure 1B Table S4 and S5).

In conclusion, we confirmed in a large population a favorable safety profile of mRNA-BNT162b2 vaccine, which may reassure on maintaining active cancer treatment throughout the whole vaccination schedule 4 . Patients with specific conditions, such as female sex and G-CSF usage, should be cautioned about increased risk of side effects. Humoral response to first dose is confirmed as inadequate 5 . Booster vaccine dose resulted in an exponential increase in IgG titer and high rate of seroconversion, arguing against delays in dosing schedule. Although some clinical features predict reduced immunogenicity, further experimental testing is required to confirm their significance.

J o u r n a l P r e -p r o o f 

Epidemiological and clinical characteristics of cancer patients with COVID-19: A systematic review and meta-analysis of global data

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer

Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

The Authors thank the entire nursing staff, as well as all patients and their families, whose commitment and helpfulness made the conduct of this study possible.

None declared.

The authors have declared no conflicts of interest.J o u r n a l P r e -p r o o f